ERAS

Erasca, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website erasca.com
Employees(FY) 129
ISIN US29479A1088

Performance

-3.42%

-8.96%

-14.48%

+24.51%

+19.25%

YTD

+35.83%

Profile

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of ERAS 2024-12-20

The Moving Average Score of 16 indicates a strong bearish sentiment, while the Oscillators Score of 50 reflects a neutral stance. Overall, the Technical Score of 33 further reinforces a bearish outlook, suggesting that the stock is currently facing downward pressure and lacks bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ERAS

Stock Rank

Recent News & Updates

2024-11-18 08:41
Jefferies Initiates Erasca at Buy With $6 Price Target(MT Newswires)
2024-11-15 09:55
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now(Zacks)
2024-11-12 16:01
Erasca Reports Third Quarter 2024 Business Updates and Financial Results(GlobeNewswire)
2024-11-12 03:01
Erasca Reports Third Quarter 2024 Business Updates and Financial Results(Globenewswire)
2024-11-05 08:00
Erasca to Present at Upcoming Investor Conferences(GlobeNewswire)
2024-11-04 19:00
Erasca to Present at Upcoming Investor Conferences(Globenewswire)
2024-10-30 11:19
Erasca Insiders Added US$1.95m Of Stock To Their Holdings(Simply Wall St.)
2024-10-24 08:00
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise(GlobeNewswire)
2024-10-23 20:00
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise(Globenewswire)
2024-09-25 08:00
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium(GlobeNewswire)
2024-09-24 20:00
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium(Globenewswire)
2024-09-23 10:09
Erasca, Inc. (NASDAQ:ERAS) is favoured by institutional owners who hold 61% of the company(Simply Wall St.)
2024-08-29 08:00
Erasca to Present at Upcoming Investor Conferences in September(GlobeNewswire)
2024-08-28 20:00
Erasca to Present at Upcoming Investor Conferences in September(Globenewswire)
2024-08-14 06:46
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely(Simply Wall St.)
2024-08-12 16:58
Erasca Q2 Loss Widens; Expects Cash to Fund Operations Until H1 of 2027(MT Newswires)
2024-08-12 16:01
Erasca Reports Second Quarter 2024 Business Updates and Financial Results(GlobeNewswire)
2024-08-12 10:53
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024(Investorplace)
2024-08-12 04:01
Erasca Reports Second Quarter 2024 Business Updates and Financial Results(Globenewswire)
2024-06-18 12:14
Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma(Clinical Trials Arena)
2024-06-18 08:00
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma(GlobeNewswire)
2024-06-17 20:00
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma(Globenewswire)
2024-06-04 09:55
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?(Zacks)
2024-06-03 21:55
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?(Zacks)
2024-05-29 08:00
Erasca to Present at Upcoming Investor Conferences in June(GlobeNewswire)
2024-05-28 20:00
Erasca to Present at Upcoming Investor Conferences in June(Globenewswire)
2024-05-23 07:00
Independent Director of Erasca Picks Up 14% More Stock(Simply Wall St.)
2024-05-23 06:30
Daily – Vickers Top Buyers & Sellers for 05/23/2024(Argus Research)
2024-05-21 16:54
Erasca Closes Oversubscribed Share Offering to Raise $184 Million(MT Newswires)
2024-05-21 16:05
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares(GlobeNewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.